212 related articles for article (PubMed ID: 27890526)
21. Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry.
Davaine JM; Querat J; Kaladji A; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
Eur J Vasc Endovasc Surg; 2015 Nov; 50(5):631-7. PubMed ID: 26342863
[TBL] [Abstract][Full Text] [Related]
22. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
23. Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery - the TRANSCEND study.
Elmariah S; Ansel GM; Brodmann M; Doros G; Fuller S; Gray WA; Pinto DS; Rosenfield KA; Mauri L
Am Heart J; 2019 Mar; 209():88-96. PubMed ID: 30685679
[TBL] [Abstract][Full Text] [Related]
24. Revascularization of the superficial femoral artery with paclitaxel-coated balloon for claudication.
Deloge C; Boesmans E; Van Damme H; Defraigne JO
Acta Chir Belg; 2018 Feb; 118(1):42-47. PubMed ID: 28891401
[TBL] [Abstract][Full Text] [Related]
25. Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results.
Stahlhoff S; Donas KP; Torsello G; Osada N; Herten M
J Endovasc Ther; 2015 Jun; 22(3):314-8. PubMed ID: 25991767
[TBL] [Abstract][Full Text] [Related]
26. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
[TBL] [Abstract][Full Text] [Related]
27. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.
Shammas NW; Shammas GA; Banerjee S; Popma JJ; Mohammad A; Jerin M
J Endovasc Ther; 2016 Apr; 23(2):339-46. PubMed ID: 26921281
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
[TBL] [Abstract][Full Text] [Related]
29. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
[TBL] [Abstract][Full Text] [Related]
30. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
31. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
[TBL] [Abstract][Full Text] [Related]
32. Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study.
Liistro F; Angioli P; Porto I; Ducci K; Falsini G; Ventoruzzo G; Ricci L; Scatena A; Grotti S; Bolognese L
J Am Coll Cardiol; 2019 Jul; 74(2):205-215. PubMed ID: 31296293
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
[TBL] [Abstract][Full Text] [Related]
34. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
Virga V; Stabile E; Biamino G; Salemme L; Cioppa A; Giugliano G; Tesorio T; Cota L; Popusoi G; Pucciarelli A; Esposito G; Trimarco B; Rubino P
JACC Cardiovasc Interv; 2014 Apr; 7(4):411-5. PubMed ID: 24630884
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
[TBL] [Abstract][Full Text] [Related]
36. Duplex-guided balloon angioplasty and stenting for femoropopliteal arterial occlusive disease: an alternative in patients with renal insufficiency.
Ascher E; Marks NA; Schutzer RW; Hingorani AP
J Vasc Surg; 2005 Dec; 42(6):1108-13. PubMed ID: 16376200
[TBL] [Abstract][Full Text] [Related]
37. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
38. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH).
Ott I; Cassese S; Groha P; Steppich B; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Hiendlmayer R; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
Circulation; 2017 Jun; 135(23):2218-2226. PubMed ID: 28424222
[TBL] [Abstract][Full Text] [Related]
39. JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study.
Shammas NW; Petruzzi N; Henao S; Armstrong EJ; Shimshak T; Banerjee S; Latif F; Eaves B; Brothers T; Golzar J; Shammas GA; Jones-Miller S; Christensen L; Shammas WJ
J Endovasc Ther; 2021 Feb; 28(1):107-116. PubMed ID: 32885736
[TBL] [Abstract][Full Text] [Related]
40. One-year outcome of the paclitaxel-eluting Legflow balloon catheter in the treatment of long and complex femoropopliteal lesions.
Bosiers M; Deloose K; Torsello G; Scheinert D; Verbist J; van den Eynde W; Maene L; Beelen R; Keirse K; Hendriks J; Callaert J; Bosiers M; Wauters J
J Cardiovasc Surg (Torino); 2020 Aug; 61(4):471-477. PubMed ID: 32241092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
